Corinne Maurice‐Dror

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee et al. · Annals of Oncology · 2021 · 273 citations · Full text

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik, Elena Garralda, Friederike Gieseke et al. · Cancer Discovery · 2022 · 104 citations · Full text

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts et al. · Nature Communications · 2024 · 101 citations · Full text

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Manish R. Patel, Todd M. Bauer, Antonio Jimeno et al. · Journal of Clinical Oncology · 2020 · 67 citations

Immunology, Immune Regulation, Pathology +23

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2021 · 66 citations

Oncology, Cancer Epidemiology, Pd-l1 Expression +12